Fusion protein technologies for biopharmaceuticals : applications and challenges / [electronic resource]
by Schmidt, Stefan R.
Material type:
BookPublisher: Hoboken, New Jersey : John Wiley & Sons, ©2013Description: 1 online resource.ISBN: 9781118354582; 1118354583; 9781118354575; 1118354575; 9781118354568; 1118354567; 9781118354599; 1118354591; 9781299241954; 1299241956.Subject(s): Biopharmaceutics | Pharmaceutical biotechnology | Drug carriers | Immunotoxins -- Therapeutic use | Protein engineering | Recombinant fusion proteins -- Therapeutic use | MEDICAL -- Pharmacology | Biopharmaceutics | Pharmaceutical biotechnology | Recombinant Fusion Proteins -- therapeutic use | Drug Carriers | Immunotoxins -- pharmacokinetics | Immunotoxins -- therapeutic use | Protein Engineering | Recombinant Fusion Proteins -- pharmacokinetics | Electronic books | Electronic booksOnline resources: Wiley Online Library Includes bibliographical references and index.
pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
Print version record and CIP data provided by publisher.
There are no comments for this item.